Skip to main content

Table 2 Correlation of ITGA5 and clinicopathological factors in STAD from Kaplan-Meier Plotter database

From: ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors

Clinicopathological characteristics

Overall survival (n = 875)

Progression free survival (n = 640)

N

Hazard ratio

P-value

N

Hazard ratio

P-value

Gender

 Female

236

2.74 (1.68–4.46)

2.6e-05

201

2.69 (1.58–4.58)

0.00014

 Male

544

2.75 (2.12–3.57)

2.2e-15

437

2.55 (2.00–3.25)

4.2e-15

Stage

 1

67

3.62 (1.00–13.12)

0.036

60

2.42 (0.63–9.31)

0.19

 2

140

2.18 (1.09–4.33)

0.023

131

1.96 (0.98–3.90)

0.051

 3

305

2.31 (1.61–3.30)

2.4e-06

186

1.87 (1.29–2.72)

8e-04

 4

148

1.78 (1.2–2.64)

0.0039

141

1.60 (1.07–2.38)

0.02

Stage T

 2

241

2.00 (1.29–3.11)

0.0015

239

1.98 (1.26–3.11)

0..0024

 3

204

1.73 (1.19–2.51)

0.0036

204

1.37 (0.98–1.91)

0.065

 4

38

2.73 (1.10–6.75)

0.025

39

3.39 (1.37–8.40)

0.0054

Stage N

 0

74

1.92 (0.82–4.46)

0.13

72

1.95 (0.85–4.49)

0.11

 1

225

3.13 (1.99–4.94)

2.3e-07

222

2.84 (1.83–4.42)

1.2e-06

 2

121

2.56 (1.62–4.05)

3.1e-05

125

2.08 (1.33–3.25)

0.00098

 3

76

2.1 (1.22–3.61)

0.0061

76

1.84 (1.02–3.33)

0.04

1 + 2 + 3

422

2.14 (1.64–2.80)

9.8e-09

423

2.30 (1.66–3.20)

2.8e-07

Stage M

 0

444

2.31 (1.66–3.21)

2.6e-07

443

2.12 (1.55–2.91)

1.6e-06

 1

56

2.66 (1.45–4.88)

0.0011

56

1.69 (0.92–3.12)

0.088

Lauren classification

 Intestinal

320

2.84 (2.07–3.90)

1.6e-11

263

2.70 (1.74–4.20)

4.2e-06

 Diffuse

241

2.00 (1.33–2.99)

0.00061

231

2.10 (1.33–3.32)

0.0012

 Mixed

32

1.88 (0.68–5.20)

0.22

28

0.48 (0.17–1.35)

0.16

Differentiation

 Poor

165

0.75 (0.50–1.12)

0.16

121

1.39 (0.79–2.45)

0.25

 Moderate

67

2.16 (1.08–4.30)

0.025

67

2.23 (1.15–4.32)

0.015

  1. STAD Stomach adenocarcinoma, N the number of patients
  2. (Please put Table 2 at the end of the paragraph which begin with the subtitle “High ITGA5 expression affects the prognosis of gastric cancer patients exhibiting lymph node metastasis”)